[1]汪志新,孟宪亮,张林.药物涂层球囊在冠状动脉小血管病变中的应用[J].国际心血管病杂志,2023,01:1-4.
点击复制
药物涂层球囊在冠状动脉小血管病变中的应用(PDF)
《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]
- 期数:
- 2023年01期
- 页码:
- 1-4
- 栏目:
- 综述
- 出版日期:
- 2023-01-20
文章信息/Info
- Title:
- -
- Author(s):
- -
- 关键词:
- 冠状动脉粥样硬化性心脏病; 药物涂层球囊; 支架; 小血管病变
- Keywords:
- -
- 分类号:
- -
- DOI:
- 10.3969/j.issn.1673-6583.2023.01.001
- 文献标识码:
- -
- 摘要:
- 药物涂层球囊（DCB）被广泛应用于支架内再狭窄，作为“介入无置入”理念 的最成熟代表，应用范围逐渐扩展。该文主要介绍DCB 在小血管病变中的应用进展。
- Abstract:
- -
参考文献/References
[1] Arslani K, Jeger R. Drug-coated balloons for small coronary
disease-A literature review[J]. Curr Cardiol Rep, 2021,
23(11):173.
[2] 赵韧, 韩雅玲. “介入无置入”理念的兴起和前景[J]. 中国
心血管杂志, 2019, 24(6):493-495．
[3] Jeger RV, Eccleshall S, Wan AWA, et al. Drug-coated balloons
for coronary artery disease[J]. JACC Cardiovasc Interv, 2020,
13(12):1391-1402.
[4] 任家孚. 药物洗脱球囊治疗冠状动脉小血管病变的研究进
展[J]. 中国循环杂志, 2018, 33(8):819-822．
[5] Buccheri D, Lombardo RM, Cortese B. Drug-coated
balloons for coronary artery disease: current concepts and
controversies[J]. Future Cardiol, 2019, 15(6):437-454.
[6] 谢江波, 陈晖, 温燕华, 等. 药物涂层球囊在冠状动脉小血管
病变中的疗效[J]. 实用医学杂志, 2019, 35(7):1092-1095．
[7] 季福绥. 药物涂层球囊在心血管领域中的应用[J]．中国临
床医生杂志, 2020, 48(8):883-885．
[8] 李晨. 冠心病患者PCI术后3年内发生支架内再狭窄情况的
高危因素影响[J]. 黑龙江医药科学, 2021, 44(6):41-42．
[9] 彭育红, 汝磊生, 牛亚辉, 等. 不宜行冠状动脉旁路移植术的
高危冠心病患者介入治疗与药物治疗的疗效对比[J]. 中华
老年多器官疾病杂志, 2018, 17(7):509-514．
[10] 王鹤儒, 张春鹏, 王宙, 等. 药物涂层球囊在经皮冠状动
脉介入术中的临床应用及研究现状[J]. 中国医药, 2019,
14(10):1583-1586．
[11] Nestelberger T, Kaiser C, Jeger R. Drug-coated balloons
in cardiovascular disease: benefits, challenges, and clinical
applications[J]. Expert Opin Drug Deliv, 2020, 17(2):201-211.
[12] Onishi T, Onishi Y, Kobayashi I, et al. Late lumen enlargement
after drug-coated balloon angioplasty for de novo coronary
artery disease[J]. Cardiovasc Interv Ther, 2021, 36(3):311-318.
[13] 杨新越, 郑悠阳, 林立, 等. 原位冠状动脉弥漫性病变药物
涂层球囊植入术后晚期管腔扩大的影响因素[J]. 山东医药,
2022, 62(7):50-52．
[14] 李占鲁, 黄翯. 紫杉醇涂层球囊的应用现状和不足以及新
一代药物涂层球囊的研究进展[J]. 中国介入心脏病学杂志,
2022, 30(4):299-302．
[15] Ali RM, Abdul Kader MASK, Wan Ahmad WA, et al.
Treatment of coronary drug-eluting stent restenosis by a
sirolimus- or paclitaxel-coated balloon[J]. JACC Cardiovasc
Interv, 2019, 12(6):558-566.
[16] 管考华，杨巍，刘世诺，等．药物涂层球囊在冠状动脉介
入治疗中的应用[J]．中国老年学杂志，2017，37(5):1297-1300．
[17] 牛振山．药物涂层球囊处理靶病变效果及对再狭窄的预防
[J]．中国药物与临床，2021，21(14):2494-2496．
[18] Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS
guidelines on myocardial revascularization: the task force
on myocardial revascularization of the European Society of
Cardiology (ESC) and the European association for Cardio-
Thoracic Surgery (EACTS)developed with the special
contribution of the European Association of Percutaneous
Cardiovascular Interventions (EAPCI)[J]. Eur Heart J, 2014,
35(37):2541-2619.
[19] Sim HW, Ananthakrishna R, Chan SP, et al. Treatment of very
small De Novo coronary artery disease with 2.0 mm drugcoated
balloons showed 1-Year clinical outcome comparable
with 2.0 mm drug-eluting stents[J]. J Invasive Cardiol, 2018,
30(7):256-261.
[20] Venetsanos D, Lawesson SS, Panayi G, et al. Longterm
efficacy of drug coated balloons compared with new
generation drug-eluting stents for the treatment of de novo
coronary artery lesions[J]. Catheter Cardiovasc Interv, 2018,
92(5):E317-E326.
[21] Cortese B, Micheli A, Picchi A, et al. Paclitaxel-coated balloon
versus drug-eluting stent during PCI of small coronary vessels,
a prospective randomised clinical trial. The PICCOLETO
study[J]. Heart, 2010, 96(16):1291-1296.
[22] Cortese B. The PICCOLETO study and beyond[J].
EuroIntervention, 2011, 7 (Suppl):K53-K56.
[23] Latib A, Colombo A, Castriota F, et al. A randomized
multicenter study comparing a paclitaxel drug-eluting balloon
with a paclitaxel-eluting stent in small coronary vessels[J]. J
Am Coll Cardiol, 2012, 60(24):2473-2480.
[24] Naganuma T, Latib A, Sgueglia GA, et al. A 2-year followup
of a randomized multicenter study comparing a paclitaxel
drug-eluting balloon with a paclitaxel-eluting stent in small
coronary vessels the BELLO study[J]. Int J Cardiol, 2015,
184:17-21.
[25] Tang Y, Qiao S, Su X, et al. Drug-coated balloon versus drugeluting
stent for small-vessel disease[J]. JACC Cardiovasc
Interv, 2018, 11(23):2381-2392.
[26] Tian J, Tang YD, Qiao SB, et al. Two-year follow-up of
a randomized multicenter study comparing a drug-coated
balloon with a drug-eluting stent in native small coronary
vessels: the RESTORE Small Vessel Disease China trial[J].
Catheter Cardiovasc Interv, 2020, 95 (Suppl 1):587-597.
[27] Jeger RV, Farah A, Ohlow MA, et al. Drug-coated balloons
for small coronary artery disease (BASKET-SMALL 2): an
open-label randomised non-inferiority trial[J]. Lancet, 2018,
392(10150):849-856.
[28] Jeger RV, Farah A, Ohlow MA, et al. Long-term efficacy and
safety of drug-coated balloons versus drug-eluting stents for
small coronary artery disease (BASKET-SMALL 2): 3-year
follow-up of a randomised, non-inferiority trial[J]. Lancet,
2020, 396(10261):1504-1510.
[29] Cortese B, Di PG, Guimaraes MG, et al. Drug-coated balloon
versus drug-eluting stent for small coronary vessel disease[J].
JACC Cardiovasc Interv, 2020, 13(24):2840-2849.
[30] Xu K, Fu GS, Tong Q, et al. Biolimus-coated balloon in smallvessel
coronary artery disease: the BIO-RISE China study[J].
JACC Cardiovasc Interv, 2022, 15(12):1219-1226.
[31] Onishi T, Onishi Y, Kobayashi I, et al. Drug-coated balloon
angioplasty for de novo small vessel disease including
chronic total occlusion and bifurcation in real-world clinical
practice[J]. Cardiovasc Interv Ther, 2019, 34(2):139-148.
[32] 陈韵岱，王建安，刘斌，等．药物涂层球囊临床应用中国
专家共识[J]．中国介入心脏病学杂志，2016，24(2):61-67.
备注/Memo
- 备注/Memo:
- 通信作者：张林，E-mail：zhanglin670108@126.com
常用功能
统计/Statistics
- 摘要浏览/Viewed0
- 全文下载/Downloads286
- 评论/Comments
